Therapy of respiratory viral infections with intranasal siRNAs

Methods in Molecular Biology

Volumn 1218, Issue , 2015, Pages 251-262

  Barik, Sailen ^a   Lu, Patrick ^a  

^a NONE

Author keywords

Antiviral; Infl uenza; Intranasal RNAi; Parainfl uenza; RSV; siRNA; siRNA cocktail

Indexed keywords

ANTIVIRUS AGENT; DOUBLE STRANDED RNA; SMALL INTERFERING RNA; CORE PROTEIN; DNA DIRECTED RNA POLYMERASE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NP PROTEIN, INFLUENZA A VIRUS; RNA BINDING PROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; DNA BASE COMPOSITION; DRUG DESIGN; DRUG EFFICACY; GENE SEQUENCE; GENETIC REASSORTMENT; GENETIC TRANSFECTION; HUMAN; IC50; INFLUENZA VIRUS; MOUSE; NONHUMAN; PARAINFLUENZA VIRUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SARS CORONAVIRUS; VIRAL RESPIRATORY TRACT INFECTION; VIROGENESIS; VIRUS CULTURE; VIRUS GENOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; EPITHELIUM CELL; GENETICS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; RESPIROVIRUS; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; VIROLOGY;

ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ADMINISTRATION, INTRANASAL; ANIMALS; CELL LINE; DNA-DIRECTED RNA POLYMERASES; EPITHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; RESPIROVIRUS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 84955406192     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1538-5_14     Document Type: Article

References (29)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specifi c genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806–811.
2. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T (2001) Functional anatomy of siRNAs for mediating effi cient RNAi in Drosophila melanogaster embryo lysate. EMBO J 20:6877–6888.
3. Bitko V, Barik S (2001) Phenotypic silencing of cytoplasmic genes using sequence-specifi c double- stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses. BMC Microbiol 1:34.
4. Bitko V, Musiyenko A, Shulyayeva O, Barik S (2004) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11:50–55.
5. Sioud M, Skorstad G, Mobergslien A, Sæbøe- Larssen S (2013) A novel peptide carrier for effi cient targeting of antigens and nucleic acids to dendritic cells. FASEB J 27:3272–3283.
6. Barik S (2004) Control of nonsegmented negative- strand RNA virus replication by siRNA. Virus Res 102:27–35.
7. Barik S (2005) Silence of the transcripts: RNA interference in medicine. J Mol Med 83: 764–773.
8. Bitko V, Barik S (2007) Intranasal antisense therapy: preclinical models with a clinical future? Curr Opin Mol Ther 9:119–125.
9. Tompkins SM, Lo CY, Tumpey TM, Epstein SL (2004) Protection against lethal infl uenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci U S A 101:8682–8686.
10. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J (2004) Inhibition of infl uenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci U S A 101: 8676–8681.
11. Li BJ, Tang Q, Cheng D, Qin C, Xie FY, Wei Q, Xu J, Liu Y, Zheng BJ, Woodle MC, Zhong N, Lu PY (2005) Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 11: 944–951.
12. Barik S (2012) New treatments for infl uenza. BMC Med 10:104.
13. Collins PL, Melero JA (2011) Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162:80–99.
14. Maggon K, Barik S (2004) New drugs and treatment for respiratory syncytial virus. Rev Med Virol 14:149–168.
15. Weinberg GA, Hall CB, Iwane MK, Poehling KA, Edwards KM, Griffi n MR, Staat MA, Curns AT, Erdman DD, Szilagyi PG (2009) New vaccine surveillance network. Parainfl uenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 154:694–699.
16. De Paula D, Bentley MV, Mahato RI (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13:431–456.
17. Oller E, Propp S, Murray H, Lima W, Bhat B, Prakash TP, Allerson CR, Swayze EE, Marcusson EG, Dean NM (2006) Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res 34:4467–4476.
18. Kraynack BA, Baker BF (2006) Small interfering RNAs containing full 2′-O-methylribonucleotide- modifi ed sense strands display Argonaute2/eIF2C2- dependent activity. RNA 12:163–176.
19. Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, Giese K, Kaufmann J (2003) Structural variations and stabilising modifi cations of synthetic siRNAs in mammalian cells. Nucleic Acids Res 31:2705–2716.
20. Sioud M, Furset G, Cekaite L (2007) Suppression of immunostimulatory siRNAdriven innate immune activation by 2′-modifi ed RNAs. Biochem Biophys Res Commun 361:122–126.
21. Sioud M (2011) Promises and challenges in developing RNAi as a research tool and therapy. Methods Mol Biol 703:173–187.
22. Chiu YL, Rana TM (2003) siRNA function in RNAi: a chemical modifi cation analysis. RNA 9:1034–1048.
23. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N, Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A, MacLachlan I, Polisky B (2005) Potent and persistent in vivo anti-HBV activity of chemically modifi ed siRNAs. Nat Biotechnol 23:1002–1007.
24. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ (2005) Synthetic dsRNA Dicer substrates enhance RNAi potency and effi cacy. Nat Biotechnol 23:222–226.
25. Siolas D, Lerner C, Burchard J, Ge W, Linsley PS, Paddison PJ, Hannon GJ, Cleary MA (2005) Synthetic shRNAs as potent RNAi triggers. Nat Biotechnol 23:227–231.
26. Amarzguioui M, Rossi JJ (2008) Principles of Dicer substrate (D-siRNA) design and function. Methods Mol Biol 442:3–10.
27. Leng Q, Woodle MC, Lu PY, Mixson AJ (2009) Advances in systemic siRNA delivery. Drugs Future 34:721.
28. Chou ST, Leng Q, Scaria P, Woodle M, Mixson AJ (2011) Cancer Gene Ther 18:707–716.
29. Simberg D, Weisman S, Talmon Y, Barenholz Y (2004) DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 21:257–317